MeSH D021441 - pancreatic ductal carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Gemcitabine | Gemcitabine | 2011-01-25 | |||
| Novast Laboratories | Gemcitabine | Gemcitabine | 2019-02-14 | |||
| Mylan | Gemcitabine | Gemcitabine | 2011-07-25 | |||
| Eli Lilly | Gemcitabine | Gemzar | 1996-05-15 | |||
| Dr Reddys Laboratories | Gemcitabine | Gemcitabine | 2011-07-25 | |||
| Sun Pharmaceutical Industries | Gemcitabine | Gemcitabine | 2011-07-25 | |||
| Gemcitabine | Infugem | 2033-07-01 | 2018-07-16 | |||
| Apotex | Gemcitabine | Gemcitabine | 2017-05-23 | |||
| Hospira | Gemcitabine | Gemcitabine | 2011-07-25 | |||
| Accord Healthcare | Gemcitabine | Gemcitabine | 2011-07-25 | |||
| Hikma Pharmaceuticals | Gemcitabine | Gemcitabine | 2021-06-25 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
57%42/74
Phase 2
18%11/62
Phase 3
21%4/19
Approved: 1Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use